Understanding how MYC gene activation affects diffuse large B-cell lymphoma
Official title: Identifying Functional Drivers of MYC Activation via Developmental Enhancers in Diffuse Large B-cell Lymphoma
Funded at University of Michigan at Ann Arbor · NIH-10880680 · Data updated 2026-11-12
This study is looking at how a gene called MYC behaves in a type of cancer called diffuse large B-cell lymphoma (DLBCL) to find new ways to improve treatments and help doctors predict how the disease will progress for patients.
Quick facts
| Grant type | R01 grant |
|---|---|
| Study type | NIH-funded research |
| Funding institution | University of Michigan at Ann Arbor NIH-funded |
| Lab location | 1 site (Ann Arbor, United States) |
| Project start | July 1, 2020 |
| Project end | June 30, 2025 |
| Funding year | 2024 |
| Award (this year) | $335,470 |
| NIH project number | 5R01CA245059-05 |
| Project ID | NIH-10880680 on NIH RePORTER |
Who could benefit from this research
✓Could help
Ideal candidates for this research are patients diagnosed with high-risk diffuse large B-cell lymphoma, particularly those without MYC genomic rearrangements.
✕Less likely to help
Patients with other types of lymphoma or those whose DLBCL is not high-risk may not benefit from this research.
What this research studies
This research investigates the role of the MYC oncogene in diffuse large B-cell lymphoma (DLBCL), a type of cancer that affects B cells. The team aims to uncover how MYC is activated through specific genetic enhancers, particularly in cases where MYC does not have typical genomic rearrangements. By using advanced techniques like CRISPR interference, they will identify the essential regulatory elements that control MYC expression. The ultimate goal is to develop better treatment strategies and predictive biomarkers for patients with DLBCL.
Why it matters
Potential benefit: If successful, this research could lead to more effective treatments and personalized therapies for patients with diffuse large B-cell lymphoma.
How similar studies have gone: Previous research has shown promising results in targeting oncogene regulation in various cancers, suggesting potential success for this novel approach.
Where this research is happening
-
University of Michigan at Ann Arbor
Ann Arbor, United States Active
Researchers
- Principal investigator: Ryan, Russell James Hubbard — University of Michigan at Ann Arbor
- Study coordinator: Ryan, Russell James Hubbard
Related research
Other NIH-funded projects on the same topics.
-
Immune Evasion by HLA-E in Diffuse Large B-Cell Lymphoma
A researcher is studying how a molecule called HLA-E helps a type of blood cancer (DLBCL) hide from the immune system, with findings that may lead to better treatments.
-
Cardioprotective treatment choices for DLBCL patients at risk of heart damage
Atrially, this study tests two heart-protecting drugs given during cancer treatment to see which best prevents heart problems in patients with diffuse large B-cell lymphoma who are at higher risk for heart damage.
-
Translating Genomics to Practice to Overcome Disparities in DLBCL
A patient-focused project aims to understand why diffuse large B-cell lymphoma outcomes differ among people and how genomic information can guide better care for diverse groups.
-
From pathogenesis to new targets for treating diffuse large B-cell lymphoma
A patient-focused look at how this research aims to uncover new genetic clues to guide targeted therapies for diffuse large B-cell lymphoma.
-
Understanding how immune features predict immunotherapy response in diffuse large B-cell lymphoma
A study to find genomic and immune markers in diffuse large B-cell lymphoma that could help predict who benefits from immunotherapies.
-
Lowering c-Myc to treat aggressive large B‑cell lymphoma
This work develops drugs that make the cancer protein c‑Myc break down, aiming to help people with aggressive large B‑cell lymphoma that overproduce c‑Myc.
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page.